Development of a Targeted Mass-Spectrometry Serum Assay To Quantify M‑Protein in the Presence of Therapeutic Monoclonal Antibodies
M-protein diagnostics can be compromised for patients receiving therapeutic monoclonal antibodies as treatment in multiple myeloma. This paper explains how a serum-based targeted mass-spectrometry assay can detect M-proteins, even in the presence of therapeutic monoclonal antibodies, leading to a correct response assessment.